(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning! - 2Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- 3Instructions to Plan for Your Teeth Substitution Methodology
- 4Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
- 5A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- The Manual for Electric Vehicles that will be hot dealers in 2023
- US FDA approves Kura-Kyowa's blood cancer therapy
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Lilly, Novo lock horns in India's obesity drug race
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Astonishing Deserts All over The Planet You Really want To Visit
